Undertreatment of common heart condition persists despite rapid adoption of novel therapies
A novel blood thinner recently approved by the FDA, dabigatran (Pradaxa), has been rapidly adopted into clinical practice, yet thus far has had little impact on improving treatment rates for atrial fibrillation. This is according ...
Sep 21, 2012